Q3 Earnings Estimate for Myomo Issued By HC Wainwright

Myomo, Inc. (NYSEAMERICAN:MYO) – Research analysts at HC Wainwright decreased their Q3 2026 EPS estimates for shares of Myomo in a research report issued on Friday, August 7th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of ($0.08) for the quarter, down from their previous estimate of ($0.07). The consensus estimate for Myomo’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Myomo’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.32) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at ($0.18) EPS, FY2029 earnings at $0.02 EPS and FY2030 earnings at $0.26 EPS.

Separately, Ascendiant Capital Markets increased their target price on shares of Myomo from $9.50 to $10.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Myomo presently has a consensus rating of “Buy” and a consensus target price of $7.50.

Myomo Stock Up 0.7%

MYO stock opened at $1.43 on Tuesday. Myomo has a twelve month low of $0.60 and a twelve month high of $1.84. The company has a quick ratio of 2.01, a current ratio of 2.31 and a debt-to-equity ratio of 1.98. The stock’s 50 day moving average is $1.15 and its 200-day moving average is $0.93. The firm has a market capitalization of $56.64 million, a PE ratio of -4.21 and a beta of 1.50.

Hedge Funds Weigh In On Myomo

A number of institutional investors and hedge funds have recently made changes to their positions in MYO. Cubist Systematic Strategies LLC raised its position in shares of Myomo by 157.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 49,101 shares of the company’s stock valued at $236,000 after purchasing an additional 30,028 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Myomo in the first quarter worth about $75,000. Jane Street Group LLC increased its position in shares of Myomo by 84.2% during the 1st quarter. Jane Street Group LLC now owns 162,658 shares of the company’s stock valued at $782,000 after purchasing an additional 74,338 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Myomo in the first quarter worth about $114,000. Finally, Geode Capital Management LLC lifted its position in shares of Myomo by 160.8% during the second quarter. Geode Capital Management LLC now owns 669,281 shares of the company’s stock worth $1,446,000 after purchasing an additional 412,631 shares during the last quarter. Hedge funds and other institutional investors own 44.99% of the company’s stock.

Insider Activity at Myomo

In related news, Director Thomas F. Kirk acquired 43,401 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was acquired at an average cost of $0.91 per share, for a total transaction of $39,494.91. Following the acquisition, the director owned 628,863 shares of the company’s stock, valued at $572,265.33. This trade represents a 7.41% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Joseph M. Jr. Manko acquired 170,830 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was purchased at an average price of $0.86 per share, with a total value of $146,913.80. Following the acquisition, the director owned 2,279,408 shares of the company’s stock, valued at $1,960,290.88. This represents a 8.10% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 341,205 shares of company stock worth $317,748 over the last three months. Insiders own 12.14% of the company’s stock.

Key Myomo News

Here are the key news stories impacting Myomo this week:

• Neutral Sentiment: HC Wainwright’s updated projections still anticipate a path to profitability, with estimated earnings of $0.02 per share in fiscal 2029 and $0.26 in fiscal 2030, although both figures were reduced from prior forecasts. Myomo analyst estimates
• Negative Sentiment: The analyst lowered its fiscal 2026 EPS forecast to a loss of $0.32 from a loss of $0.24. Quarterly estimates were also reduced to losses of $0.08 for the third quarter and $0.07 for the fourth quarter.
• Negative Sentiment: Forecasts for fiscal 2027 were cut to a loss of $0.28 per share from a loss of $0.15. HC Wainwright now expects losses in each quarter of 2027, including $0.08 in the first quarter and $0.07 in the second and third quarters.
• Negative Sentiment: The fourth-quarter 2027 estimate was reduced to a loss of $0.06 per share from expected earnings of $0.02, while the new fiscal 2028 forecast calls for a $0.18 loss.
• Negative Sentiment: Longer-term revisions were also sharply lower: fiscal 2029 EPS fell to $0.02 from $0.22, and fiscal 2030 EPS declined to $0.26 from $0.39. These cuts weaken the investment case for a company with a market capitalization of roughly $57 million and a currently negative price-to-earnings ratio.

About Myomo

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.